Prosecution Insights
Last updated: November 12, 2026
Application No. 18/833,710

ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING ATHEROSCLEROSIS AND RELATED DISEASES

Non-Final OA §112
Filed
Jul 26, 2024
Priority
Jan 29, 2022 — CN PCT/CN2022/075060 +1 more
Examiner
KIFLE, BRUCK
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Shanghai Yao Yuan Biotechnology Co. Ltd.
OA Round
1 (Non-Final)
79%
Grant Probability
Favorable
1-2
OA Rounds
95%
With Interview

Examiner Intelligence

Grants 79% — above average
79%
Career Allowance Rate
1384 granted / 1746 resolved
+19.3% vs TC avg
Strong +16% interview lift
Without
With
+15.9%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
46 currently pending
Career history
1794
Total Applications
across all art units

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1-2, 8, 11, 14, 20, 27-28, 30, 35-36, 39, 42-43, 49, 53, 58 and 60-63 are presented for examination. Claim 1 is the sole independent claim. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-2, 8, 11, 14, 20, 27-28, 30, 35-36, 39, 42-43, 49, 53, 58 and 60-63 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. i) The metes and bounds of atherosclerosis related diseases, disorders and conditions are not known. Applicants need to specifically point out which diseases are intended to be treated because the skilled artisan cannot say for sure which disease, disorder or condition, which is somehow related to atherosclerosis, is treatable by the instant claims. ii) In claim 1, third line, “a compound of Formula XI” is mentioned but the structural formula depicted is named “Formula I.” Appropriate correction is required. iii) The phrase “optionally substituted” without saying which substituents are intended is indefinite. One skilled in the art cannot say which substituents are permitted and which ones are not. iv) In claim 8, there is no definition of Formula IA as this has been deleted. Appropriate correction is required. v) In the dependent claims phrase such as, “method of claim1 having Formula IA” is in improper form. Language, such as, “wherein the compound of Formula I is a compound of Formula IA” is suggested. See claims 8, 27, 35, 39 and 42. vi) The claims are drawn to a new use of an old compound. However, medical treatment of atherosclerosis is done using statins (or other cholesterol drugs) to lower LDL, Aspirin (to prevent blood clots), blood pressure medication and other medications used to control conditions that raise the risk of atherosclerosis. Applicants need to point out what the intended treatment is directed to. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRUCK KIFLE whose telephone number is (571)272-0668. The examiner can normally be reached 8 AM - 6 PM, M-F. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey H. Murray can be reached at 571-272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. October 23, 2026 /BRUCK KIFLE/Primary Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

Jul 26, 2024
Application Filed
Oct 27, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12790302
CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHOD OF PREPARATION THEREOF
3y 5m to grant Granted Nov 10, 2026
Patent 12780782
Azirine Containing Compounds as Anti-Angiogenesis Agents and a Process for the Preparation Thereof
3y 11m to grant Granted Nov 03, 2026
Patent 12780855
PHOSPHAPHENALENE-GOLD(I) COMPLEXES AS CHEMOTHERAPEUTIC AGENTS AGAINST GLIOBLASTOMA
3y 6m to grant Granted Nov 03, 2026
Patent 12766146
Salts and Solid Form of a BTK Inhibitor
4y 5m to grant Granted Oct 20, 2026
Patent 12767637
MITOCHONDRIAL TARGETING COMPOUNDS FOR THE TREATMENT OF ASSOCIATED DISEASES
3y 11m to grant Granted Oct 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
79%
Grant Probability
95%
With Interview (+15.9%)
Low
PTA Risk
Based on 1746 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month